TY - JOUR
T1 - Localization Techniques for Non-Palpable Breast Lesions: Current Status, Knowledge Gaps, and Rationale for the MELODY Study (EUBREAST-4/iBRA-NET, NCT 05559411)
AU - Banys-Paluchowski, M.
AU - Kuehn, T.
AU - Masannat, Y.
AU - Rubio, I.
AU - de Boniface, J.
AU - Ditsch, N.
AU - Cakmak, G.K.
AU - Karakatsanis, A.
AU - Dave, R.
AU - Hahn, M.
AU - Potter, S.
AU - Kothari, A.
AU - Gentilini, O.D.
AU - Gulluoglu, B.M.
AU - Lux, M.P.
AU - Smidt, M.
AU - Weber, W.P.
AU - Sezen, B.A.
AU - Krawczyk, N.
AU - Hartmann, S.
AU - Di Micco, R.
AU - Nietz, S.
AU - Malherbe, F.
AU - Cabioglu, N.
AU - Canturk, N.Z.
AU - Gasparri, M.L.
AU - Murawa, D.
AU - Harvey, J.
N1 - Funding Information:
Maggie Banys-Paluchowski has received honoraria for lectures and participation in advisory boards: Roche, Novartis, Pfizer, pfm, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, AstraZeneca, Amgen, Samsung, MSD, GSK, Daiichi Sankyo, Gilead, Canon, Sirius Pintuition, and Pierre Fabre; and study support from Endomag, Mammotome, MeritMedical, Gilead, ExactSciences. Ash Kothari has received a research grant from Endomag and acts as PI of the respective study. Andreas Karakatsanis has received a research grant from Endomag; acts as PI of the respective study; and recieved honoraria from Pfizer and Resitu AB. Michael P. Lux received honoraria for lectures and advisory participation from Lilly, AstraZeneca, MSD, Roche, Novartis, Pfizer, Eisai, Exact Sciences, Daiichi-Sankyo, Grünenthal, Gilead, Pierre Fabre, PharmaMar, pfm, Samantree, and Endomag; travel expenses from AstraZeneca, Roche, and Pfizer; editorial board membership for medac. Francois Malherbe received honoraria and travel support from Sysmex, the local distributor of Magseed. Dawid Murawa received honoraria for lectures from Roche, Medtronic, Stryker, Mammotome, MDT—diagnostic green, GEM-Italy, Combat-Medical. Other authors declared no conflicts of interest.
Funding Information:
MELODY is supported by the AGO-B study group, the Oncoplastic Breast Consortium (OPBC), SENATURK, AWOgyn (German Working Group for Reconstructive Surgery in Oncology-Gynecology), and German Breast Group (GBG).
Publisher Copyright:
© 2023 by the authors.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Simple Summary Most breast cancers are small and can be treated using breast-conserving surgery. Since these tumors are non-palpable, they require a localization step that helps the surgeon to decide which tissue needs to be removed. The oldest localization technique is a guidewire placed into the tumor before surgery, usually using ultrasound or mammography. Afterwards, the surgeon removes the tissue around the wire tip. However, this technique has several disadvantages: It can cause the patient discomfort, requires a radiologist or another professional specialized in breast diagnostics to perform the procedure shortly before surgery, and 15-20% of patients need a second surgery to completely remove the tumor. Therefore, new techniques have been developed but most of them have not yet been examined in large, prospective, multicenter studies. In this review, we discuss all available techniques and present the MELODY study that will investigate their safety, with a focus on patient, surgeon, and radiologist preference. Background: Surgical excision of a non-palpable breast lesion requires a localization step. Among available techniques, wire-guided localization (WGL) is most commonly used. Other techniques (radioactive, magnetic, radar or radiofrequency-based, and intraoperative ultrasound) have been developed in the last two decades with the aim of improving outcomes and logistics. Methods: We performed a systematic review on localization techniques for non-palpable breast cancer. Results: For most techniques, oncological outcomes such as lesion identification and clear margin rate seem either comparable with or better than for WGL, but evidence is limited to small cohort studies for some of the devices. Intraoperative ultrasound is associated with significantly higher negative margin rates in meta-analyses of randomized clinical trials (RCTs). Radioactive techniques were studied in several RCTs and are non-inferior to WGL. Smaller studies show higher patient preference towards wire-free localization, but little is known about surgeons' and radiologists' attitudes towards these techniques. Conclusions: Large studies with an additional focus on patient, surgeon, and radiologist preference are necessary. This review aims to present the rationale for the MELODY (NCT05559411) study and to enable standardization of outcome measures for future studies.
AB - Simple Summary Most breast cancers are small and can be treated using breast-conserving surgery. Since these tumors are non-palpable, they require a localization step that helps the surgeon to decide which tissue needs to be removed. The oldest localization technique is a guidewire placed into the tumor before surgery, usually using ultrasound or mammography. Afterwards, the surgeon removes the tissue around the wire tip. However, this technique has several disadvantages: It can cause the patient discomfort, requires a radiologist or another professional specialized in breast diagnostics to perform the procedure shortly before surgery, and 15-20% of patients need a second surgery to completely remove the tumor. Therefore, new techniques have been developed but most of them have not yet been examined in large, prospective, multicenter studies. In this review, we discuss all available techniques and present the MELODY study that will investigate their safety, with a focus on patient, surgeon, and radiologist preference. Background: Surgical excision of a non-palpable breast lesion requires a localization step. Among available techniques, wire-guided localization (WGL) is most commonly used. Other techniques (radioactive, magnetic, radar or radiofrequency-based, and intraoperative ultrasound) have been developed in the last two decades with the aim of improving outcomes and logistics. Methods: We performed a systematic review on localization techniques for non-palpable breast cancer. Results: For most techniques, oncological outcomes such as lesion identification and clear margin rate seem either comparable with or better than for WGL, but evidence is limited to small cohort studies for some of the devices. Intraoperative ultrasound is associated with significantly higher negative margin rates in meta-analyses of randomized clinical trials (RCTs). Radioactive techniques were studied in several RCTs and are non-inferior to WGL. Smaller studies show higher patient preference towards wire-free localization, but little is known about surgeons' and radiologists' attitudes towards these techniques. Conclusions: Large studies with an additional focus on patient, surgeon, and radiologist preference are necessary. This review aims to present the rationale for the MELODY (NCT05559411) study and to enable standardization of outcome measures for future studies.
KW - breast cancer
KW - localization technique
KW - non-palpable lesion
KW - intraoperative ultrasound
KW - wire-guided localization
KW - magnetic seed
KW - radioactive seed
KW - radar reflector
KW - radiofrequency identification tag
KW - RADIOACTIVE SEED LOCALIZATION
KW - WIRE-GUIDED LOCALIZATION
KW - INTRAOPERATIVE ULTRASOUND GUIDANCE
KW - CARCINOMA IN-SITU
KW - CONSERVING SURGERY
KW - RADIOGUIDED LOCALIZATION
KW - CARBON LOCALIZATION
KW - AGO RECOMMENDATIONS
KW - REOPERATION RATES
KW - CANCER PATIENTS
U2 - 10.3390/cancers15041173
DO - 10.3390/cancers15041173
M3 - (Systematic) Review article
C2 - 36831516
SN - 2072-6694
VL - 15
JO - Cancers
JF - Cancers
IS - 4
M1 - 1173
ER -